Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis

Levi, 2010, Circadian timing in cancer treatments, Annu Rev Pharmacol Toxicol, 50, 377, 10.1146/annurev.pharmtox.48.113006.094626 Zhang, 2010, Clocks not winding down: unravelling circadian networks, Nat Rev Mol Cell Biol, 11, 764, 10.1038/nrm2995 Innominato, 2009, Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer, Cancer Res, 69, 4700, 10.1158/0008-5472.CAN-08-4747 Innominato, 2010, Regulation of circadian rhythms and hypothalamic–pituitary–adrenal axis: an overlooked interaction in cancer, Lancet Oncol, 11, 816, 10.1016/S1470-2045(10)70171-6 Li, 2010, Cancer inhibition through circadian reprogramming of tumor transcriptome with meal timing, Cancer Res, 70, 3351, 10.1158/0008-5472.CAN-09-4235 Lévi, 2007, Circadian rhythms: mechanisms and therapeutic implications, Annu Rev Pharmacol Toxicol, 47, 593, 10.1146/annurev.pharmtox.47.120505.105208 Lévi, 1994, Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial, J Natl Cancer Inst, 86, 1608, 10.1093/jnci/86.21.1608 Levi, 1997, Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy, Lancet, 350, 681, 10.1016/S0140-6736(97)03358-8 Giacchetti, 2006, J Clin Oncol, 24, 3562, 10.1200/JCO.2006.06.1440 Petit, 1988, Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients, Cancer Res, 48, 1676 Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, Ann Intern Med, 151, 264, 10.7326/0003-4819-151-4-200908180-00135 Maughan, 2011, Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial, Lancet, 377, 2103, 10.1016/S0140-6736(11)60613-2 Douillard, 2010, Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study, J Clin Oncol, 28, 4697, 10.1200/JCO.2009.27.4860 Saltz, 2008, Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study, J Clin Oncol, 26, 2013, 10.1200/JCO.2007.14.9930 Cassidy, 2011, XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results, Br J Cancer, 105, 58, 10.1038/bjc.2011.201 Levi, 2011, Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability, Cancer Chemother Pharmacol, 67, 339, 10.1007/s00280-010-1327-8 Rich, 2005, Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer, Clin Cancer Res, 11, 1757, 10.1158/1078-0432.CCR-04-2000 Adam, 2009, Patients with initially unresectable colorectal liver metastases: is there a possibility of cure?, J Clin Oncol, 27, 1829, 10.1200/JCO.2008.19.9273 Smith, 2004, Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01, J Natl Cancer Inst, 96, 1128, 10.1093/jnci/djh220 Adler, 2010, When separate is more equal, J Am Med Assoc, 304, 2738, 10.1001/jama.2010.1865 Elsaleh, 2000, Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer, Lancet, 355, 1745, 10.1016/S0140-6736(00)02261-3 Roth, 2010, Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial, J Clin Oncol, 28, 466, 10.1200/JCO.2009.23.3452 Press, 2008, Gender-related survival differences associated with EGFR polymorphisms in metastatic colon cancer, Cancer Res, 68, 3037, 10.1158/0008-5472.CAN-07-2718 Karatsoreos, 2011, Androgens modulate structure and function of the suprachiasmatic nucleus brain clock, Endocrinology, 152, 1970, 10.1210/en.2010-1398 Schwab, 2008, Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group, J Clin Oncol, 26, 2131, 10.1200/JCO.2006.10.4182 Chansky, 2005, Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma, Cancer, 103, 1165, 10.1002/cncr.20878 Milano, 1992, Influence of sex and age on fluorouracil clearance, J Clin Oncol, 10, 1171, 10.1200/JCO.1992.10.7.1171 Shitara, 2009, Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX, Eur J Cancer, 45, 1757, 10.1016/j.ejca.2009.01.019 Innominato, 2011, Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963), Chronobiol Int, 28, 586, 10.3109/07420528.2011.597532 Levi, 2007, Implications of circadian clocks for the rhythmic delivery of cancer therapeutics, Adv Drug Deliv Rev, 59, 1015, 10.1016/j.addr.2006.11.001 Cain, 2010, Sex differences in phase angle of entrainment and melatonin amplitude in humans, J Biol Rhythms, 25, 288, 10.1177/0748730410374943 Bjarnason, 2010, Gender differences in rhythmic gene expression in human chronic lymphocytic leukemia cells and T-cells in nine patients: Impact of melatonin therapy on the timing of peak expression